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Episialin (MUC1) Inhibits Cytotoxic 
Lymphocyte-Target Cell Interaction
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Abstract. Episialin (MUC1) is a mucin-like glycoprotein abundantly expressed on most carcinoma cells. As a result 
of its extended and rigid structure, it reduces intercellular adhesion. We investigated whether this antiadhesion 
function allows tumor cells expressing high levels of episialin to escape from immune recognition. To test this 
hypothesis, we transfected episialin-negative (episialin™) melanoma cells (A375) with the MUC1 cDNA-encoding 
episialin. The results demonstrated that episialin-positive (episialin'1') melanoma cells were significantly less sus­
ceptible to lysis than episialin”  melanoma cells by both alloantigen or rlL-2-stimulated cytotoxic effector cells. In 
addition, cold target inhibition experiments with episialin+ and episialin" cells clearly demonstrated preferential 
lysis of episialin”  cells. Furthermore, antibody blocking studies showed that lysis of episialin+, but not of episialin” , 
melanoma cells was predominantly dependent on the leukocyte function-associated Ag-1 /intracelIular adhesion 
molecule adhesion route, suggesting that episialin+ target cells adhere less efficiently to effector cells than episialin" 
target cells. This notion was supported by the observation that conjugate formation of the effector cells with 
episial in“1“ target cells was significantly impaired. From these results we conclude that over-expression of episialin 
as found on many tumor cells may indeed affect efficient lysis by cytotoxic lymphocytes and thus may contribute 
to escape from immune surveillance. Journal o f Immunology, 1993, 151: 767.
E pisialin is a transmembrane, mucin-like glycopro­
tein encoded by the MUC1 gene. It is mainly 
present on glandular epithelial cells, and its ex­
pression is substantially increased in many carcinomas (1). 
Full-length cDNA encoding episialin has been cloned and 
sequenced. The large extra cellular domain consists mainly 
of repeats of 20 amino acids (2-5). As a result of a genetic 
polymorphism, the number of these repeats varies between 
about 30 and 90, causing a variation in length of the protein 
between 1000 and 2200 amino acids. Episialin contains
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many proline, serine, and threonine residues and numerous 
O-linked carbohydrate side chains (2-5). These character­
istics indicate that episialin has a rigid structure and extends 
far above the plasma membrane, and thus, if present in 
sufficient quantity, this cell surface molecule would effec­
tively shield the cells from interactions with other cells and 
macromolecules (6). We previously showed that expression 
of large amounts of episialin on the cell surface after trans­
fection with episialin cDNA prevents homotypic aggrega­
tion of melanoma or mammary epithelial cells. Similarly, 
aggregation of episialin”4 cells with episialin* mammary 
epithelial cells is disturbed (7). In contrast to this antiad­
hesion effect of episialin, it has also been shown that epi­
sialin can elicit a specific cytotoxic T cell response (8). It 
was suggested that this is the result of a differential gly- 
cosylation of the repeated structure of the molecule. This 
repeated epitope can be recognized by TCR in a MHC non­
restricted manner (8, 9).
4 Abbreviations used in this paper; episialin'1", episialin-positive; episialin-, 
episialin-negative; LAK cells, lymphokine activated killer cells; ICAM, intra­
cellular adhesion molecule; LPA, leukocyte function-associated Ag.
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Despite the fact that episialin can induce a TCR- 
mediated immune response, the antiadhesion function of 
episialin has led to the hypothesis that high expression of 
episialin on tumor cells may also result in escape from the 
immune system. Both specific (TCR-mediated) and non­
specific (without TCR involvement) cytotoxic activity of 
lymphocytes require cellular interactions with their target 
cells (10). These cellular interactions are not only mediated 
by the TCR/CD3 complex but also by a number of acces­
sory molecules, including CD4, CDS, CD2, and LFA-1, 
which bind to their respective ligands, MHC class II, MHC 
class I, LFA-3, and ICAM-1 (11).
In the present study, we investigated whether expression 
of high levels of episialin by target cells, will affect their 
ability to be recognized by cytotoxic lymphocytes. If epi­
sialin indeed impairs cell-cell contact, this may have im­
portant consequences for the survival of tumor cells in the 
circulation, and may thus contribute to the metastatic pro­
cess. We, therefore, transfected the episialin” human mel­
anoma cell line A375 with cDNA-encoding episialin and 
tested both episialin* and episialin*" melanoma cells for 
their susceptibility to nonspecific lysis by lymphokine- 
activated peripheral blood lymphocytes, or to TCR/CD3- 
mediated lysis by T lymphocytes, alloantigen stimulated in 
mixed lymphocyte-tumor cell culture with A375 melanoma 
cells.
Material and Methods
Cell lines and cell cultures
Mononuclear cell suspensions of healthy volunteers were 
fractionated by centrifugal élutriation as described previ­
ously (12). The cell fraction containing T lymphocytes 
(CD2+, CD3+) and NK cells (CD2+, CD3-) was cultured 
for 5 days in Iscove’s medium supplemented with 5% hu­
man serum, 1% antibiotic/myotic solution (Flow, Irvine, 
Scotland) and 0.2% kanamycin solution (Sigma, St. Louis, 
MO), and stimulated with 500 IU/ml rIL-2, kindly provided 
by Eurocetus (Amsterdam, The Netherlands) before they 
were used as LAK cells. This LAK cell population con­
tained approximately 20% CD3-, CD2+, CD56+, and 
CD57+ cells (NK cells). Table I shows the phenotype of a 
representative LAK cell population.
Freshly isolated allogeneic PBL (1 X  106/ml), mixed 
with 1 X  104/ml-irradiated A375 melanoma cells (100 Gy) 
were maintained in Iscove’s medium supplemented with 
5% human serum, antibiotic/myotic, and kanamycin. The 
PBL were restimulated, once a week, with irradiated A375 
cells to generate an alio specific response. In addition, after 
3 wk of culturing, rIL-2 (100 IU/ml) was added weekly, and 
after 4 wk, also a mixture of feeder cells [irradiated (50 Gy) 
allogeneic EB V-transformed B cells and irradiated (40 Gy) 
allogeneic PBL, stimulated with 0.2 /xg/ml phytohemag­
glutinin] was added biweekly to further stimulate growth of
Table I
Phenotype of cytotoxic effector cells
Ag mAb
Positive Cells (%)
LAK CTL
Control 6 2
CD2 CLB-T11/1 94 100
CD3 CLB-T3/3 74 100
TCRa/3 BMA031 73 100
CD4 RIV-6 37 12
CD8 WT82 36 84
CD56 Leu 19 21 8
CD57 Leu 7 14 2
CD16 CLB-FcGr/1 32 4
CD20 B1 6 4
effector cells. After 8 wk of stimulation, the lymphocyte 
culture had acquired a stable phenotype and was used as 
effector cells (cytotoxic T lymphocytes). All CTL ex­
pressed the a/3TCR, and the main population was CD8+ 
(Table I). Both effector cells (LAK cells and CTL) were 
LFA“1+, LFA-3+, and ICAM-1+ . The expression levels of 
these Ag were comparable on both type of effector cells.
The melanoma cell lines A375 (13), Me Wo (14) and 
518A2 (15), and the MHC-negative, LAK-sensitive pro- 
erythroleukemia cell line K562 were maintained in Iscove’s 
medium supplemented with 10% FCS, antibiotic/myotic, 
and kanamycin. All cell lines were free of mycoplasma 
contamination.
Transfection and generation of revertant A375 
melanoma cells
Cloned A375 cells (A375B, further referred to as A375 
cells) were transfected with the expression vector 
pCMVIE-AK1 -DHFR (16), in which the coding domain of 
episialin cDNA was inserted, and the DHFR gene was re­
moved (7). The vector contains a neomycin-resistance 
gene. Transfections were performed using the calcium- 
phosphate co-precipitation method (5). After 3 wk, neo­
mycin resistant clones were isolated and the expression of 
episialin was examined by FACScan (Becton Dickinson, 
Mountain View, CA) analysis as described previously (17). 
To generate revertant melanoma cells, episialin* A375 
cells were cultured in the absence of neomycin. Episialin"" 
cells were 2 to 4 times sorted by FACS tar (Becton Dick­
inson), expanded by in vitro culturing and analyzed for the 
lack of episialin by FACScan. One episialin'1' cell line 
(ACA25F4-) was cloned to select a cell line with high epi­
sialin expression and a cell line that lost episialin expression 
(ACA25F8+ and ACA25F2-, respectively). These cell 
lines were expanded by in vitro culturing and analyzed for 
expression of episialin by FACScan using mAb 139H2 
(18).
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mAb
The following mAb were used for phenotypic analysis and 
for functional inhibition studies. 139H2 (anti-episialin) was 
generated as described previously (18). The following mAb 
were kindly provided by several laboratories: CLB-LFA- 
1/1 (anti-LFA-1 common /3 chain, CD18) (19) (Dr. F. 
Miedema, Amsterdam, The Netherlands); CLB-T11/1 
(anti-CD2) and CLB-T3/3 (anti-CD3) (20) (Dr. R. A. W. 
van Lier, Amsterdam, The Netherlands); F10.2 (anti- 
ICAM-1, CD54) (21) (Dr. A. C. Bloem, Utrecht, The Neth­
erlands); RIV-6 (anti-CD4) (22) (Dr. F. UytdeHaag, 
Bilthoven, The Netherlands); WT82 (anti-CD8) (23) (Dr. 
W. J. M. Tax, Nijmegen, The Netherlands); CLB-Fc-Gr/1 
(anti-CD 16) (24) (Dr. T. W. J. Huizinga, Amsterdam, The 
Netherlands); TS2/9 (anti-LFA-3, CD58) (25) (Dr. T. A. 
Springer, Boston, MA); W6/32 (anti-MHC class I) (26) (Dr.
C. J. Barnstable, Oxford, England); BMA 031 (anti- 
TCRajS) (27) (Dr. R. Kurrle, Marburg, Germany); B1 (anti- 
CD20) (28) (Coulter Corporation, Hialeah, FL); Leu 7 
(anti-CD57) (29) and Leu 19 (anti-CD56) (30) (Becton 
Dickinson, San Jose, CA).
Immunofluorescence
Cells were incubated (30 min, 0°C) in PBS, containing
0.5% wt/vol BSA (Sigma), and 0.02% wt/vol sodium azide, 
with appropriate dilution of the different mAb, followed by 
incubation with FITC-labeled goat F(ab')2 anti-mouse IgG 
antibody (GAM-FITC, Nordic, Tilburg, The Netherlands) 
for 30 min at 0°C. The relative fluorescence intensity was 
measured on a FACScan (Becton Dickinson).
Cytotoxicity assay
The 1 X 103-labeled target cells (100 ¡ id  51Cr/106 cells, 
Amersham, Buckinghamshire, UK) were placed in each 
well of V-bottom microtiter plates with varying numbers of 
effector cells in 150 ¡jl 1 Iscove’s medium with 0.25% BSA. 
The plates were centrifuged for 5 min at 50 g and incubated 
at 37°C and 5% C02. After the incubation period, 100 ¡jl\  
of supernatant was collected from each well and counted in 
a gamma counter. All tests were carried out in triplicate. 
Specific lysis was determined as the percentage of the net 
maximal 51Cr release by detergent. Spontaneous release in 
the absence of CTL was <25% of maximal release by de­
tergent in all experiments.
Heterotypic cell conjugate formation assay
Heterotypic cell conjugates were quantitatively determined 
by a double fluorescence assay (31). Melanoma target cells 
(2 X 106 cells/ml) were stained with the red dye Hydro- 
ethidine [HE (Polyscience, Inc., Warrington, PA); 40 mg/ml 
in MN-dimethylacetonide] at concentrations of 3 ng/ml, 
and lymphocytes (LAK cells and CTL) (2 X 106 cells/ml)
with the green dye sulfofluorescein diacetate (SFDA, Mo­
lecular Probes, Junction City, OR) at a concentration of 5 
jLLg/ml in Iscove’s medium with 10% FCS. After 1 h of 
incubation at 37°C, cells were washed twice in Iscove’s 
medium with 10% FCS. Cells were seeded in round-bottom 
wells (5 X 104 HE-labeled and 5 X 104 SFDA-labeled 
cells) in 100 ¡A. After incubation at room temperature, cells 
were fixed with 0.5% wt/vol paraformaldehyde, and the 
number of conjugates was counted by FACScan. Double­
colored conjugates were calculated as a percentage of the 
total HE-colored events counted.
Binding of lymphocytes to episialin-transfected and 
-reverted melanoma cells
Transfected and reverted A375 cells (2 X 104 cells/well) 
were grown in Iscove’s medium containing 5% FCS in flat 
bottom 96-well plates (Costar, Cambridge, MA). After 3 
days of culturing, the cell monolayers were washed. CTL 
were labeled with 51Cr for 1.5 to 2 h, washed, and resus­
pended in Iscove’s medium with 0.25% wt/voi BSA. Then, 
2 X 104 radio-labeled CTL cells were added in triplicate 
(100 jlxI final volume) to the monolayers of transfected and 
reverted melanoma cells and incubated for 30 min at 37°C 
and 5% C02. Unbound cells were removed by washing 
gently with Iscove’s medium containing 0.25% wt/vol 
BSA. Bound cells were lysed by detergent, and the radio­
activity of the cell lysate was counted in a gamma counter. 
Results were expressed as the mean percentage of cell bind­
ing from triplicate wells.
Results
Episialin expression by A375, transfectants and 
revertants
We have generated three sets of episialin-transfected cell 
lines (ACA19D4+, ACA25F8+, ACA30D8+) and rever­
tants of these lines, which have lost the episialin expression 
(ACA19D4", ACA25F2~, ACA30D8”). Immunofluores­
cence analysis showed a high level of episialin expression 
on transfected A375 melanoma ceils (ACA19D4'1', 
ACA25F8*f\ ACA30D8+), whereas parental (A375) and 
revertant melanoma cell lines (ACA19D4-, ACA25F2", 
ACA30D8-) expressed no episialin on their cell surface 
(Table II). The level of episialin expression by transfected 
cells was comparable to that observed on carcinoma cell 
lines (data not shown). Furthermore, the m.w. of the pre­
cursor and mature forms of episialin expressed by the trans­
fectants were comparable to that of the T47D cells, the cell 
line from which the cDNA had been derived (7). Further 
phenotypical analysis of cell surface expression of 
ICAM-1, LFA-3, and MHC class I molecules involved in 
cytolytic interaction revealed that all cell surface markers 
tested were expressed as well as on the parental cell line 
A375 as on the episialin-transfected and -reverted cell lines,
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Table II
Phenotypical analysis o f parental, transfected, and reverted 
melanoma cell lines
Table III
Cytotoxic activity o f CTL and LAK cells against a number o f 
targets cell lines
Relative Fluorescence Intensity
Cell Line
Cytotoxicity {%)a
Cell line
Control Ag Episialin 
ÍCLB-LFÁ-1/1) (139H2)
ICAM-1 
(FI 0.2)
LFA-3
(TS2/9)
HLA class 1 
(W6/32)
CTL
Medium Anti-CD3
LAK
Medium Anti-CD3
A3 75 8 4 148 51 164 A3 75 77 39 63 66
ACA25F2- 7 12 155 45 240 ACA19D4- 45 24 52 58
ACA25F8+ 9 2142 97 32 113 ACA19D4+ 23 11 36 33
ACA19D4- 10 17 131 65 129 ACA30D8- 79 26 69 75
ACA19D4+ 9 1590 91 41 89 ACA30D8+ 59 29 58 54
ACA30D8- 6 9 215 47 362 518A 12 NT0 57 NT
ACA3QD8+ 9 1092 134 35 295 M e W o
K562
16
14
NT
NT
68
69
NT
NT
although the levels of expression were lower on episialin* 
cells (Table II). This is probably due to the fact that high 
episialin expression affects accessibility of the antibodies 
to their respective Ag, since capping of episialin on the cell 
surface diminished this effect (data not shown).
a Percentage cytotoxicity after 3 h of incubation. Effector-target ceil ratio 
30:1, SE in all tests is less than 7%. 
b Not tested.
Lysis of episialin transfected melanoma cells
We investigated the susceptibility to lysis of episialin- 
transfected melanoma cell lines (AC A19D4+, ACA25F8+, 
ACA30D8+), reverted melanoma cell lines (ACA19D4", 
ACA25F2-, ACA30D8-), the parental cell line (A375), two 
unrelated melanoma cell lines (MeWo and 518A), and the 
NK~ and LAK-sensitive target cell line (K562), To this end, 
we used two types of effector cells: 1) alloantigen stimu-
target cell line K562 was not killed by CTL, whereas it 
showed a high susceptibility to LAK cell activity (Fig. 2 A 
and B). Cytotoxicity assays performed with an effector- 
target cell ratio of 10 to 1 showed comparable results (data 
not shown).
From these results, we conclude that episialin- 
transfected melanoma cells are less susceptible to lysis than 
reverted melanoma cells and the parental cells. Further­
more, we conclude that the alloantigen-stimulated CTL 
preferentially lyse A375- and A375-derived cell lines.
Effector cells preferentially lyse episialin target cells
lated CTL and 2) LAK cells. The specificity of both effector 
cells is illustrated in Table III. The CTL lysed the melanoma 
cell lines used as allogeneic stimulator cells, whereas two 
unrelated melanoma cell lines and K562 were not lysed. In To further investigate whether CTL preferentially lysed the 
contrast with CTL, LAK cells lysed all target cell lines episialin- target cells, we performed cold target inhibition
(Table III). Furthermore, the involvement of the TCR/CD3 
complex in lysis by CTL is demonstrated by addition of
studies. Addition of unlabeled episialin cells (ACA30D8 ) 
significantly inhibited lysis of both radio-labeled episialin+
anti-CD3 mAb that significantly inhibited lysis by CTL and episialin target cells. Lysis of radio-labeled episialin+
(48% to 66%), whereas this mAb was incapable of inhib- cells (ACA30D8 ) was already maximally inhibited after
iting nonspecific lysis by LAK cells (Table III).
In addition, we studied the susceptibility to lysis of epi­
sialin + and episialin” cells after various incubation times. 
The results in Figure 1A -C  show that episialin+ melanoma 
cells were less susceptible to lysis than episialin- melanoma 
cells by CTL. We also measured the percentage lysis of 
ACA30D8+ and ACA30D8“ by LAK cells. Episialin+
addition of equal numbers of unlabeled episialin+ cells, 
whereas inhibition of lysis of episialin" targets
(ACA30D8-) required the addition of significantly larger 
numbers of unlabeled cells (Fig. 3). Addition of unlabeled 
episialin4* cells affected lysis of radio-labeled target cells 
significantly less. An 4- to 8-fold excess of unlabeled 
ACA30D8+ cells was required to obtain a substantial in­
melanoma cells were lysed considerably slower compared hibition of lysis of radio-labeled target cells (Fig. 3). Ad-
to episialin- target cells by LAK cells (Fig. ID). Although 
ACA30D8-1" cells are less well lysed than the ACA30D8“ 
cells, after 4 h of incubation almost similar amounts of Comparable results were obtained using ACA19D4-
dition of unlabeled K562 cells did not significantly alter the 
allospecific lysis of both radio-labeled target cells (Fig. 3).
target cell were lysed. This is most likely due to the rela­
tively low episialin expression by this transfectant com-
transfected and -reverted melanoma cells (data not shown). 
These results confirm the conclusion that episialin + mel- 
pared to the other transfected target cell lines (Table II). The anoma cells are less susceptible to lysis than episialin" mel- 
cytotoxic activity of both effector cell types against the anoma cells. Importantly, these blocking data also substan- 
parental cell line A375, (Fig. 2 A and B ) was comparable tiate that episialin does not simply reduce the intrinsic 
to that against the reverted cell lines. The LAK-sensitive ability of target cells to be lysed.
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FIGURE 1. The kinetics of lysis of episialin- target cells (O), and episialin'1' positive target cells (•). A, Cytotoxic activity of 
CTL against ACA19D4“, ACA19D4+; B, cytotoxic activity of CTL against ACA25F2", ACA25F8+; C, cytotoxic activity of CTL 
against ACA30D8~, ACA30D8+; and D, cytotoxic activity of rlL-2 activated killer (LAK) cells against ACA30D8-, ACA3QD8^\ 
The effector-target cell ratio was 30:1. One representative experiment out of four is shown.
Episialin affects adhesion of effector cells to target 
cells
Next we examined the capacity of the episialin + target cells 
(ACA19D4+, ACA30D8+) and episialin“ target cells 
(ACA19D4~, ACA30D8~) to form conjugates with the var­
ious cytotoxic effector cells (LAK cells, CTL). After 2 h of 
incubation, no effector-target cell conjugates (LAK cells) 
or only a very low number of conjugates (CTL) were 
formed with episialin-1" cells, whereas 20% and 40% of 
episialin“ cells formed conjugates with LAK cells and CTL, 
respectively (Fig. 4A).
Similar results were obtained when CTL were allowed to
bind to a monolayer of episialin-transfected melanoma cells 
or revertants. Figure 4B shows that less CTL bound to epi- 
sialin* melanoma cells than to episialin” cells.
From these results, we conclude that episialin expression 
on melanoma cells strongly decreases binding to 
lymphokine-activated killer cells as well as alloantigen 
activated CTL.
Distinct cell adhesion pathways participate in the 
cytolytic process
We investigated whether episialin expression affected the 
contribution of the various adhesion pathways, in particular
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FIGURE 2. Lysis of both control cell lines: the LAK-sensitive target cell line K562 (□) and the parental melanomacell line 
A375 (■). A, Cytotoxicity of CTL; and B, cytotoxicity of rIL-2 activated killer (LAK) cells. The effector-target cell ratio was 30:1. 
One representative experiment out of four is shown.
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LFA-l/ICAM-1 and CD2/LFA-3, in the cytotoxic process. 
Therefore, we performed mAb inhibition assays. Both 
lymphokine-stimulated and alloantigen-stimulated cyto­
toxic activity against episialin* melanoma cells could be 
inhibited by addition of mAb directed against LFA-1 and 
ICAM-1 (60%), whereas lysis of episialin- melanoma cells 
was much less affected (25% to 15%) (Fig. 5). In contrast, 
blocking of the CD2/LFA-3 adhesion route resulted in a 
significant inhibition of specific lysis (CTL) of both epi­
sialin + (45%) and episialin" targets (37%), whereas non­
specific lysis (LAK) was much less affected (Fig. 5). Block­
ing both adhesion routes (LFA-1 ¡1CAM-1 and CD2/LFA-3) 
showed additive inhibition (Fig. 5).
From these results, we can conclude that the LFA-1/ 
ICAM adhesion route is mainly involved in lysis of epi- 
sialin+ melanoma cells, whereas lysis of episialin- cells can 
be regulated by other adhesion routes. The CD2/LFA-3 in­
teraction plays a substantial role in the lysis of the mela­
noma cells by alloantigen-activated effector cells, whereas 
this interaction is not significantly involved in lysis by 
lymphokine-activated killer cells.
Discussion
We have previously demonstrated that episialin expressed 
on melanoma cells interferes with cell-cell interaction and 
prevents homotypic aggregation of these transfected cells 
(7). The cytolytic process, however, requires a heterotypic 
attachment of effector cells to target cells, mediated by mul­
tiple adhesion receptors and their ligands (32), We hypoth­
esized that episialin expressed by potential target cells 
(tumor cells) could prevent effector-target cell conjugation 
and might contribute to the escape of the tumor cells from 
immune surveillance. The observations that the human mu­
cin DF3 (episialin) is able to inhibit adhesion of eosinophils 
to antibody-coated targets (33) and that sialomucins, ex­
pressed on rat mammary tumor cells, contribute to resis­
tance to natural killer cell-mediated lysis (34), are consis­
tent with this hypothesis. This hypothesis is also supported 
by a number of observations that emerge from this study: 
1) episialin+ melanoma cells are significantly less suscep­
tible to lysis than episialin- melanoma cells by both specific 
and nonspecific effector cells. This finding is supported by
Journal of Immunology 7 7 3
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FIGURE 4. Binding of CTL to episiaiin-transfected and -reverted melanoma cells. A, The kinetics of heterotypic conjugate 
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ACA25F8* and episialin-reverted melanoma cells ACA19D4" and ACA25F2“. One representative experiment out of two is 
shown.
the observation that unlabeled episialin'' cells inhibit lysis 
of labeled target cells more efficiently than unlabeled epi­
sialin+ cells. 2) Conjugate formation of both types of cy­
totoxic effector cells (CTL, LAK cells) with episialin* tar­
get cells can hardly be measured by flow cytometry. 
Moreover, using another cell adhesion assay (CTL adhesion 
to monolayers of melanoma cells), which is less sensitive 
to disruption of CTL-target cell binding, it is demonstrated 
that CTL adhere significantly less well to episialin4- mel­
anoma cells than to episialin- melanoma cells. Neverthe­
less, a significant proportion of the episialin* target cells 
can be lysed after prolonged times of incubation. These 
observations may be explained by a brief and unstable con­
tact between effector cells and episialin* target cells. Not 
all contact events result in stable adhesion and subsequent 
lysis of target cells, whereas stable attachment of effector 
cells to episialin" target cells will result more frequently in 
target cell lysis. This may also explain the slow kinetics of 
lysis of episialin* target cells. 3) The observation that the 
addition of mAb against LFA-1 and ICAM-1 inhibits lysis
of episialin* cells and not that of episialin" cells by specific 
and nonspecific effector cells, suggests that this adhesion 
route, which is involved in the initial contact phase of the 
cytolytic process (10), is of critical importance in binding 
effector cells to episialin* target cells. This observation 
provides further evidence for the assumption that conju­
gates of effector cells with episialin* target cells are un­
stable and that lysis of these cells requires long incubation 
periods. Furthermore, it is possible that episialin expression 
on target cells interfere with effector cell activation. If clus­
tering of receptor molecules is required for this activation, 
the accessibility of binding sites on the target cells might 
be disturbed by episialin.
In contrast to the almost complete inhibition of cytotoxic 
activity of CTL and LAK cells against episialin* melanoma 
cells by blocking the two major adhesion pathways (LFA- 
1/ICAM-l and CD2/LFA-3), a substantial percentage of 
episialin" cells is lysed without utilization either one of 
these two important adhesion pathways (especially by LAK 
cells). This observation suggests that in the cytolytic pro-
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FIGURE 5, Inhibition of adhesion path­
ways involved in cytotoxic activity of effec­
tor cells (LAK and CTL) against episialin* 
and episialin- melanoma cell lines. 10 
pg/ml purified IgG of each mAb was present 
in the cytotoxicity assay (4 h). The effector- 
target cell ratio was 30:1. One representa­
tive experiment out of six is shown.
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cess against episialin“ melanoma cells, a role is reserved for 
other adhesion pathways besides LFA-l/ICAM-1 and CD2/ 
LFA-3. Melanoma cells express high levels of distinct ad­
hesion molecules of the /31 and /33 group of the integrin 
family, which are receptor molecules for extra cellular ma­
trix components (35,36). These molecules may be involved 
in the cytolytic interaction; however, cellular ligands for 
most of the J31 and j33 adhesion receptors have not been 
described. Only the interaction of VLA-4, a /31 integrin, 
with a cellular ligand, VCAM-1 expressed on endothelial 
cells, has been documented (37, 38). The clear distinction 
between episialin" and episialin1" melanoma ceils in uti­
lizing additional adhesion molecules may be the result of 
masking the molecules involved in adhesion routes by epi­
sialin. Particularly, the interaction of small transmembrane 
molecules may be hindered by the long and rigid structure 
of episialin. This might also explain why some surface mol­
ecules on episialin* cells seem less well expressed com­
pared to those on episialin“ cells. Probably, the high epi­
sialin expression caused a reduced accessibility for mAb 
directed against many other surface molecules.
Recently, we have observed that episialin* melanoma 
cells, when injected i.v,, metastasize in nude mice more 
efficiently compared to episialin" melanoma cells (J. H, 
and F. B., unpublished results). This may suggest that epi­
sialin* melanoma cells are less susceptible to the cellular 
immune response mediated by nonspecific cytotoxic ef­
fector ceils (NK cells) in nude mice. However, the differ­
ences in adhesion properties of the episialin * and episialin' 
melanoma cells may not only decrease the sensitivity to the 
cellular immune response but may also lead to differences 
in the invasiveness and migration of both cell types.
Finally, it has been reported that despite its anti adhesion 
function, episialin is still capable of provoking a T cell- 
mediated immune response, in which an epitope frequently 
exposed on the repeats of episialin derived by tumor cells 
is recognized by TCR in a MHC nonrestricted manner (8). 
Activation of CTL is probably due to TCR cross-linking by 
specific recognition of repeated epitopes (9). These MHC 
nonrestricted cytotoxic T lymphocytes were generated from 
tumor-draining lymph nodes of patients with breast and 
pancreatic cancers (8,9). This suggests that the epitope that
journal of Immunology 775
is preferentially expressed on malignant cells is capable of 
inducing an in vivo immune response. However, free epi- 
sialin sheded by the tumor cells might inhibit the activity 
of cytotoxic T lymphocytes and thereby protect the tumor 
cells from this immune recognition.
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